{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:58:10Z","timestamp":1790373490194,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":959,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13311-021-01051-4","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T10:02:57Z","timestamp":1619085777000},"page":"6-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["A practical guide to the pharmacological and behavioral therapy of Narcolepsy"],"prefix":"10.1016","volume":"18","author":[{"given":"Christian","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-0472","authenticated-orcid":false,"given":"Giuseppe","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01051-4_bib1","unstructured":"AASM: American Academy of Sleep Medicine. ICSD-3: international classification of sleep disorders, 3rd edn. Amer Acad Sleep Med, Daniel (IL) 2014."},{"key":"10.1007\/s13311-021-01051-4_bib2","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01051-4_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1","article-title":"The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding","volume":"62","author":"Sutcliffe","year":"2000","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-021-01051-4_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0028-3908(00)00178-7","article-title":"Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat","volume":"40","author":"Brown","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-021-01051-4_bib5","first-page":"14","article-title":"Epidemiology and Pathophysiology of Childhood Narcolepsy","volume":"25","author":"Dye","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1007\/s13311-021-01051-4_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neures.2008.01.017","article-title":"Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb","volume":"61","author":"Shibata","year":"2008","journal-title":"Neurosci Res"},{"key":"10.1007\/s13311-021-01051-4_bib7","first-page":"228","article-title":"An epidemiological study of narcolepsy in Japanese","volume":"1","author":"Tashiro","year":"1992","journal-title":"J Sleep Res"},{"key":"10.1007\/s13311-021-01051-4_bib8","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.50.2_Suppl_1.S16","article-title":"Genetic and familial aspects of narcolepsy","volume":"50","author":"Mignot","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01051-4_bib9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.5665\/sleep.3756","article-title":"Challenges in diagnosing narcolepsy without cataplexy: a consensus statement","volume":"37","author":"Baumann","year":"2014","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41439-018-0033-7","volume":"6","author":"Miyagawa","year":"2019","journal-title":"Genetics of narcolepsy. Hum Genome Var"},{"key":"10.1007\/s13311-021-01051-4_bib11","doi-asserted-by":"crossref","unstructured":"Fronczek R, Arnulf I, Baumann CR, Maski K, Pizza F, Trotti LM. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep 2020;43.","DOI":"10.1093\/sleep\/zsaa044"},{"key":"10.1007\/s13311-021-01051-4_bib12","doi-asserted-by":"crossref","first-page":"e38977","DOI":"10.1371\/journal.pone.0038977","article-title":"Non-dipping blood pressure profile in narcolepsy with cataplexy","volume":"7","author":"Dauvilliers","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01051-4_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0035-1550152","article-title":"Narcolepsy during Childhood: An Update","volume":"46","author":"Rocca","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1007\/s13311-021-01051-4_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.sleep.2012.08.002","article-title":"The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes","volume":"13","author":"Ingravallo","year":"2012","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.slsci.2014.07.001","article-title":"Narcolepsy and the Sickness Impact Profile: A general health status measure","volume":"7","author":"Ton","year":"2014","journal-title":"Sleep Sci"},{"key":"10.1007\/s13311-021-01051-4_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy","volume":"13","author":"Maski","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.5664\/jcsm.8088","article-title":"Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort","volume":"15","author":"Pascoe","year":"2019","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib18","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1523\/JNEUROSCI.20-22-08620.2000","article-title":"Hypothalamic arousal regions are activated during modafinil-induced wakefulness","volume":"20","author":"Scammell","year":"2000","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01051-4_bib19","first-page":"139","article-title":"Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions","volume":"7","author":"Wisor","year":"2013","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-1331.2006.01473.x","article-title":"EFNS guidelines on management of narcolepsy","volume":"13","author":"Billiard","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1176\/jnp.17.3.405","article-title":"Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness","volume":"17","author":"Schwartz","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1007\/s13311-021-01051-4_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","article-title":"Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy","volume":"26","author":"Schwartz","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00002826-200403000-00005","article-title":"Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness","volume":"27","author":"Schwartz","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib25","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/sleep\/17.suppl_8.S107","article-title":"Modafinil: a double-blind multicentric study","volume":"17","author":"Billiard","year":"1994","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib26","doi-asserted-by":"crossref","unstructured":"Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444\u2013451.","DOI":"10.1212\/WNL.49.2.444"},{"key":"10.1007\/s13311-021-01051-4_bib27","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54:1166\u20131175.","DOI":"10.1212\/WNL.54.5.1166"},{"key":"10.1007\/s13311-021-01051-4_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/sleep\/22.6.757","article-title":"Health-related quality of life effects of modafinil for treatment of narcolepsy","volume":"22","author":"Beusterien","year":"1999","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib29","doi-asserted-by":"crossref","unstructured":"Thakrar C, Patel K, D'ancona G, et al. Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. J Sleep Res 2018;27:e12627.","DOI":"10.1111\/jsr.12627"},{"key":"10.1007\/s13311-021-01051-4_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.2000.00271.x","article-title":"Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation","volume":"50","author":"Palovaara","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079906X100050","article-title":"The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy","volume":"22","author":"Harsh","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1007\/s13311-021-01051-4_bib32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","article-title":"Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Szakacs","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib34","doi-asserted-by":"crossref","unstructured":"Lehert P, Szoeke C. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach. Drugs Context 2020;9.","DOI":"10.7573\/dic.2020-6-2"},{"key":"10.1007\/s13311-021-01051-4_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01051-4_bib36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1007\/s13311-021-01051-4_bib37","first-page":"273","article-title":"The effects of gamma-hydroxybutyrate on sleep","volume":"12","author":"Mamelak","year":"1977","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-021-01051-4_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/jsr.12468","article-title":"Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy","volume":"26","author":"Roth","year":"2017","journal-title":"J Sleep Res"},{"key":"10.1007\/s13311-021-01051-4_bib39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.sleep.2011.10.032","article-title":"Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study","volume":"13","author":"Mansukhani","year":"2012","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib40","first-page":"31","article-title":"A 12-month, open- label multicenter extension trial of orally administered sodium oxybate for the reatment of narcolepsy","volume":"26","author":"US Xyrem Multicenter Study Group","year":"2003","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.sleep.2005.03.010","article-title":"Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients","volume":"6","author":"Xyrem International Study Group","year":"2005","journal-title":"Sleep Med."},{"key":"10.1007\/s13311-021-01051-4_bib42","doi-asserted-by":"crossref","unstructured":"U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119\u2013123","DOI":"10.1016\/j.sleep.2003.11.002"},{"key":"10.1007\/s13311-021-01051-4_bib43","unstructured":"PDR.net. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm332029.htm 2016."},{"key":"10.1007\/s13311-021-01051-4_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2352-4642(18)30133-0","article-title":"Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation","volume":"2","author":"Plazzi","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1007\/s13311-021-01051-4_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-020-00744-2","article-title":"Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial","volume":"34","author":"Dauvilliers","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-021-01051-4_bib47","doi-asserted-by":"crossref","unstructured":"Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 2020;43.","DOI":"10.1093\/sleep\/zsz220"},{"key":"10.1007\/s13311-021-01051-4_bib48","unstructured":"Sleepfoundation.org. Sleep Apnea | National Sleep Foundation [online]. Available at: https:\/\/www.sleepfoundation.org\/sleep-disorders-problems\/sleep-apnea 2019."},{"key":"10.1007\/s13311-021-01051-4_bib49","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/sleep\/9.1.260","article-title":"Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline","volume":"9","author":"Mitler","year":"1986","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib51","doi-asserted-by":"crossref","unstructured":"Mayer G, Ewert Meier K, Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995;18:306\u2013319.","DOI":"10.1097\/00002826-199508000-00002"},{"key":"10.1007\/s13311-021-01051-4_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.smrv.2011.09.001","article-title":"Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Boscolo-Berto","year":"2012","journal-title":"Sleep Med Rev"},{"key":"10.1007\/s13311-021-01051-4_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5664\/jcsm.2048","article-title":"Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis","volume":"8","author":"Alshaikh","year":"2012","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib55","first-page":"42","article-title":"A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","author":"US Xyrem Multicenter Study Group","year":"2002","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib56","doi-asserted-by":"crossref","unstructured":"Mayer G, Plazzi G, Iranzo \u00c1, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep 2018;41.","DOI":"10.1093\/sleep\/zsy128"},{"key":"10.1007\/s13311-021-01051-4_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","article-title":"The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use","volume":"33","author":"Kollb-Sielecka","year":"2017","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib58","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep 201921;42.","DOI":"10.1093\/sleep\/zsz174"},{"key":"10.1007\/s13311-021-01051-4_bib59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","article-title":"Fluoxetine in the treatment of cataplexy","volume":"9","author":"Langdon","year":"1986","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11940-017-0459-0","article-title":"Cataplexy and Its Mimics: Clinical Recognition and Management","volume":"19","author":"Pillen","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5664\/jcsm.2848","article-title":"Status cataplecticus precipitated by abrupt withdrawal of venlafaxine","volume":"9","author":"Wang","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.44.4.707","article-title":"Fluoxetine suppresses human cataplexy: a pilot study","volume":"44","author":"Frey","year":"1994","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01051-4_bib63","doi-asserted-by":"crossref","unstructured":"Thirumalai null, Shubin null. The use of citalopram in resistant cataplexy. Sleep Med 1 2000;1:313\u2013316.","DOI":"10.1016\/S1389-9457(00)00026-5"},{"key":"10.1007\/s13311-021-01051-4_bib64","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1212\/01.wnl.0000175978.61048.62","article-title":"Unusually prolonged rebound cataplexy after withdrawal of fluoxetine","volume":"65","author":"Poryazova","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01051-4_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.43.2.171","article-title":"Fluvoxamine and clomipramine in the treatment of cataplexy","volume":"43","author":"Schachter","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01051-4_bib66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archneur.1975.00490520023002","article-title":"Treatment of Cataplexy with Clomipramine","volume":"32","author":"Shapiro","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0404.1976.tb07621.x","article-title":"Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride","volume":"54","author":"Guilleminault","year":"1976","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-021-01051-4_bib68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2869.2011.00991.x","article-title":"Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy","volume":"21","author":"Lecendreux","year":"2012","journal-title":"J Sleep Res."},{"key":"10.1007\/s13311-021-01051-4_bib69","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/sleep\/33.11.1457","article-title":"Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children","volume":"33","author":"Aran","year":"2010","journal-title":"Sleep."},{"key":"10.1007\/s13311-021-01051-4_bib70","first-page":"293","article-title":"A review of modafinil film-coated tablets for attention-deficit\/hyperactivity disorder in children and adolescents","volume":"3","author":"Rugino","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-021-01051-4_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1389-9457(03)00162-X","article-title":"Modafinil in the treatment of excessive daytime sleepiness in children","volume":"4","author":"Ivanenko","year":"2003","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","article-title":"Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness","volume":"35","author":"Inocente","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib73","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2174\/1389200219666180305153134","article-title":"Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy","volume":"19","author":"Moresco","year":"2018","journal-title":"Curr Drug Metab."},{"key":"10.1007\/s13311-021-01051-4_bib74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/sleep\/29.8.1025","article-title":"Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate","volume":"29","author":"Murali","year":"2006","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2018.03.020","article-title":"Impact of acute administration of sodium oxybate on heart rate variability in children with type 1 narcolepsy","volume":"47","author":"Antelmi","year":"2018","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib76","doi-asserted-by":"crossref","unstructured":"Filardi M, Pizza F, Antelmi E, Ferri R, Natale V, Plazzi G. In-field assessment of sodium oxybate effect in pediatric type 1 narcolepsy: an actigraphic study. Sleep 2018;41.","DOI":"10.1093\/sleep\/zsy050"},{"key":"10.1007\/s13311-021-01051-4_bib77","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1592\/phco.29.6.656","article-title":"Attention-deficit-hyperactivity disorder: an update","volume":"29","author":"Dopheide","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1007\/s13311-021-01051-4_bib78","unstructured":"Product information. Dextroamphetamine sulfate oral tablets, dextroamphetamine sulfate oral tablets. St. Louis, MO: Mallinckrodt 2007."},{"key":"10.1007\/s13311-021-01051-4_bib79","unstructured":"Product information. RITALIN: oral tablets, methylphenidate hydrochloride oral tablets. East Hanover, NJ: Novartis 2007."},{"key":"10.1007\/s13311-021-01051-4_bib80","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fpsyt.2020.00717","article-title":"Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment","volume":"11","author":"Boaden","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1007\/s13311-021-01051-4_bib81","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.5664\/jcsm.3284","article-title":"Treatment of cataplexy in a three-year-old using venlafaxine","volume":"9","author":"Ratkiewicz","year":"2013","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2008.036","article-title":"Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations","volume":"19","author":"M\u00f8ller","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1007\/s13311-021-01051-4_bib83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.sleep.2008.04.004","article-title":"Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy","volume":"10","author":"Ristanovic","year":"2009","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib84","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","article-title":"Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset","volume":"56","author":"Dauvilliers","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib85","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","article-title":"Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy","volume":"255","author":"Plazzi","year":"2008","journal-title":"J Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/WNL.0b013e31825dce03","article-title":"Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency","volume":"79","author":"Knudsen","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01051-4_bib87","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5664\/jcsm.6500","article-title":"Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study","volume":"13","author":"Lecendreux","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1671072","article-title":"Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-Up","volume":"2018","author":"Ruppert","year":"2018","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib89","series-title":"Narcolepsy: a clinical guide","first-page":"217","article-title":"Narcolepsy, driving and traffic safety","author":"Donjacour","year":"2010"},{"key":"10.1007\/s13311-021-01051-4_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.sleep.2010.07.008","article-title":"A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy","volume":"12","author":"Vignatelli","year":"2011","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib91","series-title":"Narcolepsy: a clinical guide","first-page":"231","article-title":"Medico-legal aspects of disability in narcolepsy","author":"Ingravallo","year":"2010"},{"key":"10.1007\/s13311-021-01051-4_bib92","series-title":"Narcolepsy: a clinical guide","first-page":"239","article-title":"Narcolepsy and mental health","author":"Shneerson","year":"2010"},{"key":"10.1007\/s13311-021-01051-4_bib93","series-title":"Narcolepsy: a clinical guide","first-page":"205","article-title":"Narcolepsy, intima1cy and sexuality","author":"Lindsley","year":"2010"},{"key":"10.1007\/s13311-021-01051-4_bib94","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14656566.2013.783021","article-title":"Pharmacotherapy options for cataplexy","volume":"14","author":"Lopez","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-021-01051-4_bib95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2869.2006.00533.x","article-title":"Cognitive deficits in narcolepsy","volume":"15","author":"Naumann","year":"2006","journal-title":"J Sleep Res"},{"key":"10.1007\/s13311-021-01051-4_bib96","series-title":"Narcolepsy: a clinical guide","first-page":"223","article-title":"Memory and cognition in narcolepsy","author":"Bellebaum","year":"2010"},{"key":"10.1007\/s13311-021-01051-4_bib97","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.2008.161588","article-title":"Psychological health in central hypersomnias: the French Harmony study","volume":"80","author":"Dauvilliers","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1007\/s13311-021-01051-4_bib98","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","article-title":"Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population","volume":"14","author":"Ohayon","year":"2013","journal-title":"Sleep Med."},{"key":"10.1007\/s13311-021-01051-4_bib99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/15402002.2015.1120201","article-title":"Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study","volume":"15","author":"Neikrug","year":"2017","journal-title":"Behav Sleep Med."},{"key":"10.1007\/s13311-021-01051-4_bib100","unstructured":"Alaia SL. Life Effects of Narcolepsy. null 1992;5:1\u201322."},{"key":"10.1007\/s13311-021-01051-4_bib101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000432400","article-title":"Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics","volume":"71","author":"Plazzi","year":"2015","journal-title":"Neuropsychobiology."},{"key":"10.1007\/s13311-021-01051-4_bib102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1071\/PY01003","article-title":"Achieving control over sleepiness in narcolepsy","volume":"7","author":"Bruck","year":"2001","journal-title":"Australian journal of primary health."},{"key":"10.1007\/s13311-021-01051-4_bib103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00004650-199607000-00008","article-title":"Symptom description and management in narcolepsy","volume":"10","author":"Cohen","year":"1996","journal-title":"Holist Nurs Pract."},{"key":"10.1007\/s13311-021-01051-4_bib104","doi-asserted-by":"crossref","unstructured":"Daniels E, King MA, Smith IE, Shneerson JM. Health-related quality of life in narcolepsy. J Sleep Res 2001;10:75\u201381.","DOI":"10.1046\/j.1365-2869.2001.00234.x"},{"key":"10.1007\/s13311-021-01051-4_bib105","doi-asserted-by":"crossref","first-page":"e01955","DOI":"10.1002\/brb3.1955","article-title":"Impact of COVID-19 pandemic lockdown on narcolepsy type 1 management","volume":"11","author":"Postiglione","year":"2021","journal-title":"Brain Behav"},{"key":"10.1007\/s13311-021-01051-4_bib106","unstructured":"Britton T, Hansen A, Hicks J, Howard R, Meredith A. Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-Based Guidelines for the UK with Graded Recommendations. Ashtead, UK: Taylor Patten Communications Ltd 2002."},{"key":"10.1007\/s13311-021-01051-4_bib107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/S1516-44462010000300016","article-title":"Brazilian guidelines for the treatment of narcolepsy","volume":"32","author":"Al\u00f3e","year":"2010","journal-title":"Braz J Psychiatry."},{"key":"10.1007\/s13311-021-01051-4_bib108","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/sleep\/24.4.385","article-title":"A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy","volume":"24","author":"Rogers","year":"2001","journal-title":"Sleep."},{"key":"10.1007\/s13311-021-01051-4_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122478","article-title":"Health-related stigma as a determinant of functioning in young adults with narcolepsy","volume":"10","author":"Kapella","year":"2015","journal-title":"PLoS One."},{"key":"10.1007\/s13311-021-01051-4_bib110","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1389-9457(11)70203-9","article-title":"Multicomponent Cognitive Behavioral treatment efficacy for narcolepsy (MCBT-N)","volume":"12","author":"Marin-Agudelo","year":"2011","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib111","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jsmc.2012.03.005","article-title":"Behavioral management of hypersomnia","volume":"7","author":"Conroy","year":"2012","journal-title":"Sleep Med Clin"},{"key":"10.1007\/s13311-021-01051-4_bib112","unstructured":"Mar\u0131\u00b4n-Agudelo H, Jime\u00b4nez Correa U. Scheduled naps and systematic desensitization in the emotional processing in patients with narcolepsy: a comparative study of autonomic and cognitive evoked potentials. Sleep 2012;35: A275"},{"key":"10.1007\/s13311-021-01051-4_bib113","unstructured":"Mar\u00edn-Agudelo H, Jim\u00e9nez Correa U. Beliefs and dysfunctional attitudes in patients with narcolepsy; double-blind study of treatment efficacy. Sleep 2013;36."},{"key":"10.1007\/s13311-021-01051-4_bib114","doi-asserted-by":"crossref","unstructured":"Ong JC, Dawson SC, Mundt JM, Moore C. Developing a cognitive behavioral therapy for hypersomnia using telehealth: a feasibility study. J Clin Sleep Med 2020;16:2047\u20132062.","DOI":"10.5664\/jcsm.8750"},{"key":"10.1007\/s13311-021-01051-4_bib115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/sleep\/16.5.444","article-title":"Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy","volume":"16","author":"Mullington","year":"1993","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib116","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/sleep\/9.1.167","article-title":"Daytime sleep characteristics and their relationships with night sleep in the narcoleptic patient","volume":"9","author":"Billiard","year":"1986","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib117","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5664\/jcsm.4554","article-title":"Quality measures for the care of patients with narcolepsy","volume":"11","author":"Krahn","year":"2015","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-021-01051-4_bib118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/sleep\/20.4.251","article-title":"The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals","volume":"20","author":"Helmus","year":"1997","journal-title":"Sleep."},{"key":"10.1007\/s13311-021-01051-4_bib119","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jsmc.2020.02.018","article-title":"Nonpharmacologic Management of Excessive Daytime Sleepiness","volume":"15","author":"Ebben","year":"2020","journal-title":"Sleep Med Clin."},{"key":"10.1007\/s13311-021-01051-4_bib120","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jnu.12515","article-title":"Update on Research and Practices in Major Sleep Disorders: Part II-Insomnia, Willis-Ekbom Disease (Restless Leg Syndrome), and Narcolepsy","volume":"51","author":"Chaiard","year":"2019","journal-title":"J Nurs Scholarsh."},{"key":"10.1007\/s13311-021-01051-4_bib121","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0013-4694(94)90071-X","article-title":"Differential effects of extended sleep in narcoleptic patients","volume":"91","author":"Uchiyama","year":"1994","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1007\/s13311-021-01051-4_bib122","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/sleep\/30.11.1417","article-title":"Running promotes wakefulness and increases cataplexy in orexin knockout mice","volume":"30","author":"Espa\u00f1a","year":"2007","journal-title":"Sleep"},{"key":"10.1007\/s13311-021-01051-4_bib123","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fneur.2018.00707","article-title":"Physical Activity and Sleep\/Wake Behavior, Anthropometric, and Metabolic Profile in Pediatric Narcolepsy Type 1","volume":"9","author":"Filardi","year":"2018","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib124","doi-asserted-by":"crossref","unstructured":"Filardi M, Pizza F, Antelmi E, Pillastrini P, Natale V, Plazzi G. Physical Activity and Sleep\/Wake Behavior, Anthropometric, and Metabolic Profile in Pediatric Narcolepsy Type 1. Front Neurol 2018;9:707.","DOI":"10.3389\/fneur.2018.00707"},{"key":"10.1007\/s13311-021-01051-4_bib125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.slsci.2014.07.023","article-title":"Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy?","volume":"7","author":"Mar\u00edn Agudelo","year":"2014","journal-title":"Sleep Sci"},{"key":"10.1007\/s13311-021-01051-4_bib126","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5664\/jcsm.8286","article-title":"Giving a voice to cataplectic experience: recollections from patients with narcolepsy type 1","volume":"16","author":"Franceschini","year":"2020","journal-title":"J Clin Sleep Med."},{"key":"10.1007\/s13311-021-01051-4_bib127","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0020-7489(02)00092-5","article-title":"Peer support within a health care context: a concept analysis","volume":"40","author":"Dennis","year":"2003","journal-title":"Int J Nurs Stud"},{"key":"10.1007\/s13311-021-01051-4_bib128","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3389\/fpsyg.2020.01353","article-title":"Can a Peer Support the Process of Self-Management in Narcolepsy? A Qualitative Narrative Analysis of a Narcoleptic Patient","volume":"11","author":"Franceschini","year":"2020","journal-title":"Front Psychol."},{"key":"10.1007\/s13311-021-01051-4_bib129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pec.2013.02.002","article-title":"The experience and impact of chronic disease peer support interventions: a qualitative synthesis","volume":"92","author":"Embuldeniya","year":"2013","journal-title":"Patient Educ Couns"},{"key":"10.1007\/s13311-021-01051-4_bib130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/dmcn.12091","article-title":"Peer support for parents of children with chronic disabling conditions: a systematic review of quantitative and qualitative studies","volume":"55","author":"Shilling","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1007\/s13311-021-01051-4_bib131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-8-22","article-title":"Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support","volume":"11","author":"Anderson","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-021-01051-4_bib132","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1367493516643420","article-title":"Psychosocial intervention for children with narcolepsy: Parents' expectations and perceived support","volume":"20","author":"Kippola-P\u00e4\u00e4kk\u00f6nen","year":"2016","journal-title":"J Child Health Care"},{"key":"10.1007\/s13311-021-01051-4_bib133","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5665\/sleep.4582","article-title":"Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination","volume":"38","author":"Szak\u00e1cs","year":"2015","journal-title":"Sleep."},{"key":"10.1007\/s13311-021-01051-4_bib134","doi-asserted-by":"crossref","unstructured":"Szak\u00e1cs A, Hallb\u00f6\u00f6k T, Tideman P, Darin N, Wentz E. Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination. Sleep. 2015 Apr 1;38(4):615\u201321.","DOI":"10.5665\/sleep.4582"},{"key":"10.1007\/s13311-021-01051-4_bib135","doi-asserted-by":"crossref","unstructured":"Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med 2013 Sept 15;9(9):955\u201365.","DOI":"10.5664\/jcsm.3004"},{"key":"10.1007\/s13311-021-01051-4_bib136","unstructured":"European Commission. Implementation report on the Commission communication on rare diseases: Europe's challenges and Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Available at: http:\/\/ec.europa.eu\/health\/rare_diseases\/docs\/2014_rarediseases_implementationreport_en.pd"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01051-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:59:57Z","timestamp":1761807597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1878747923011753"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01051-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical guide to the pharmacological and behavioral therapy of Narcolepsy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01051-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}